[go: up one dir, main page]

AR128106A1 - Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead - Google Patents

Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead

Info

Publication number
AR128106A1
AR128106A1 ARP220103587A ARP220103587A AR128106A1 AR 128106 A1 AR128106 A1 AR 128106A1 AR P220103587 A ARP220103587 A AR P220103587A AR P220103587 A ARP220103587 A AR P220103587A AR 128106 A1 AR128106 A1 AR 128106A1
Authority
AR
Argentina
Prior art keywords
tead
yap
taz
inhibitors
pharmaceutically acceptable
Prior art date
Application number
ARP220103587A
Other languages
English (en)
Inventor
Bart Vanderhoydonck
Arnaud Marchand
Aurlie Candi
Matthias Versele
Original Assignee
The Katholieke Univ Leuven
Springworks Therapeutics Inc
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Katholieke Univ Leuven, Springworks Therapeutics Inc, Vib Vzw filed Critical The Katholieke Univ Leuven
Publication of AR128106A1 publication Critical patent/AR128106A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto con la fórmula (1), o un estereoisómero, tautómero, sal farmacéuticamente aceptable. Reivindicación 12: Una composición farmacéutica que comprende el compuesto de cualquiera de las reivindicaciones 1 - 11 o un estereoisómero, tautómero, sal farmacéuticamente aceptable, o solvato de este, y un portador farmacéuticamente aceptable. Reivindicación 18: Un método para la prevención o el tratamiento de trastornos mediados por la activación de YAP / TAZ-TEAD en un animal, mamífero o ser humano, que comprende administrar a dicho animal, mamífero o ser humano que necesita dicha prevención o tratamiento una dosis eficaz de los compuestos de cualquiera de las reivindicaciones 1 - 11. Reivindicación 19: Un método para el tratamiento o la prevención de un trastorno mediado por la activación de YAP / TAZ-TEAD de acuerdo con la reivindicación 17 a un paciente que lo necesita en combinación con uno o más medicamentos seleccionados del grupo que consiste en inhibidores de EGFR, inhibidores de MEK, inhibidores de AXL, inhibidores de B-RAF e inhibidores de RAS.
ARP220103587A 2021-12-23 2022-12-26 Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead AR128106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163293536P 2021-12-23 2021-12-23

Publications (1)

Publication Number Publication Date
AR128106A1 true AR128106A1 (es) 2024-03-27

Family

ID=86903814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103587A AR128106A1 (es) 2021-12-23 2022-12-26 Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead

Country Status (9)

Country Link
US (1) US12378202B2 (es)
EP (1) EP4452948A4 (es)
JP (1) JP2025500505A (es)
AR (1) AR128106A1 (es)
AU (1) AU2022420025A1 (es)
CA (1) CA3244064A1 (es)
MX (1) MX2024007937A (es)
TW (1) TW202334091A (es)
WO (1) WO2023122781A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202423428A (zh) 2022-09-29 2024-06-16 香港商英矽智能科技知識產權有限公司 Tead抑制劑及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572235A3 (en) * 1992-05-28 1994-06-01 Tanabe Seiyaku Co Beta-carboline derivatives with anticholecystoquinine activity
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP6141428B2 (ja) * 2012-07-13 2017-06-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗増殖性ベンゾ［ｂ］アゼピン−２−オン
EP3156404A1 (en) 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
US11091501B2 (en) * 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
AU2020241258B2 (en) 2019-03-15 2025-09-11 The General Hospital Corporation Novel small molecule inhibitors of TEAD transcription factors
CN119462659A (zh) * 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
AU2020282759A1 (en) * 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
JP2023544719A (ja) * 2020-09-30 2023-10-25 カトリーケ・ユニフェルシテイト・ルーヴァン がん治療のためのｙａｐ／ｔａｚ－ｔｅａｄ活性の阻害剤としての１，２，３，４－テトラヒドロキノリン誘導体

Also Published As

Publication number Publication date
CA3244064A1 (en) 2023-06-29
EP4452948A4 (en) 2025-12-17
EP4452948A2 (en) 2024-10-30
US20230278962A1 (en) 2023-09-07
TW202334091A (zh) 2023-09-01
JP2025500505A (ja) 2025-01-09
AU2022420025A1 (en) 2024-07-18
WO2023122781A2 (en) 2023-06-29
MX2024007937A (es) 2024-09-18
US12378202B2 (en) 2025-08-05
WO2023122781A3 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
AR129238A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
CL2021003202A1 (es) Compuestos de pirrolidina
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
DOP2025000044A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
CL2022000889A1 (es) Inhibidores del factor d del complemento para administración oral
AR128106A1 (es) Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
UY39516A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
MX2025014866A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos
CL2025001119A1 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
BR112022022628A2 (pt) Inibidor de dhodh para o tratamento de covid-19
AR133135A1 (es) Compuestos que modulan kras